 The main questions being addressed are 1 how patient reported outcomes change during treatment for HCV, 2 how treatment impacts liver function and liver status, and 3 how much treatment costs from the payers perspective and the patients perspective. The hypothesis being tested is that treatment has a negative effect on the quality of life during treatment. The negative effect is expected to be temporary. Successful treatment, which is equated with a virological cure of the infection, is expected to result in an improvement in quality of life compared to baseline and to improvement in markers of liver function and liver status. Costs of treatment are expected to be 80,000-200,000 per virological cure. 